Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: application of a numerical scoring system for evaluating sequential morphologic changes.
In order to assess the sequential changes of liver pathology after interferon therapy, 70 liver biopsy specimens, collected from 23 HBeAg-positive patients with chronic hepatitis B and 12 patients with chronic non-A, non-B hepatitis, were studied using a numerical scoring system proposed by Knodell et al. The biopsy specimens were obtained immediately prior to the administration of interferon and within one week following the termination of interferon therapy. Three patients with chronic hepatitis B were negative for DNA-polymerase (DNA-P) prior to the interferon administration. Ten patients (50%) lost DNA-P activity. HBeAg became negative in 8 patients (34.8%), of whom 2 seroconverted to anti-HBe. Serum alanine aminotransferase levels normalized in 9 patients with chronic hepatitis B, and non-A, non-B hepatitis. The total Histological Activity Index (HAI) scores in both patients with chronic hepatitis B, and non-A, non-B decreased significantly (P less than 0.001 and P less than 0.005, respectively) after interferon treatment. There was also a significant improvement (0.02 less than P less than 0.001) in each histological category except for fibrosis. When the changes of the HAI scores in patients with chronic hepatitis B were correlated to the outcome in the DNA-P and HBeAg/anti-HBe system after treatment, the histological improvement did not significantly correlate to the outcome of these serological parameters.
Okuno
T
T
Department of Internal Medicine, Akashi Municipal Hospital, Japan.
Shindo
M
M
Arai
K
K
Matsumoto
M
M
Takeda
M
M
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D002908:Chronic Disease; D004259:DNA-Directed DNA Polymerase / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis / Q000276:immunology; D006526:Hepatitis C / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000473:pathology / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology*; D008103:Liver Cirrhosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009336:Necrosis
D006510:Hepatitis B Antibodies; D006513:Hepatitis B e Antigens; D007370:Interferon Type I; D000410:Alanine Transaminase; D004259:DNA-Directed DNA Polymerase